Waters H, Goyal R, Strouss L, Legacy S, Nagar S, Wilbanks J. Regional differences in HEDIS measure results for schizophrenia treatment adherence in state Medicaid programs. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 19, 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S62.
Stanford RH, Nagar S, Lin X, O'Connor RD. Use of ICS/LABA on asthma exacerbation risk in patients within a medical group. J Manag Care Pharm. 2015 Nov;21(11):1014-9.
Hogue S, Hollis K, Silvia S, Wooddell M, White MV. Staff training and use of epinephrine auto-injectors for the treatment of anaphylaxis: results from the EPIPEN4SCHOOLS survey. Poster presented at the 2015 AMCP Nexus; October 27, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10a):s7.
Mladsi D, Ramamohan V, Ronquest N, Boklage SH. A cost-consequences analysis of inpatient tolvaptan compared with fluid restriction among SIADH patients with hyponatremia. Poster presented at the 2015 AMCP Nexus; October 26, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10-a):S33.
Ramamohan V, Mladsi D, Ronquest N, Boklage S. A cost-consequences analysis of inpatient tolvaptan compared with fluid restriction among CHF patients with hyponatremia. Poster presented at the 2015 AMCP Nexus; October 26, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10-a):S53.
Dalal AA, Patel JP, D'Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Pharm. 2015 Jul;21(7):575-83.
Korsnes JS, Davis KL, Ariely R, Bell C, Mitra D. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events. J Manag Care Pharm. 2015 Jun;21(6):443-50.
DaCosta Byfield S, McPheeters JT, Burton T, Nagar SP, Hackshaw MD. Persistence and compliance among US patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma. J Manag Care Pharm. 2015 Jun;21(6):515-22.
Maglinte G, Graham C, Schwartzberg L, Price T, Knox H, Hechmati G, Hjelmgren J, Barber B, Fakih M. Economic analysis of panitumumab versus cetuximab in chemorefractory patients with wild-type KRAS metastatic colorectal cancer. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 9, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S11-2.
Wilson M, Mody R, Ursan I, Carr S. The budgetary impact of vedolizumab in the management of moderately to severely active ulcerative colitis and Crohn's disease in the United States. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S57.
Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.
Wang T, Meyers J, Davis K, Madhwani S, Boklage S. Patterns of H. pylori treatment and testing for patients in a commercially insured population. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 1, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr; 21(4-a):S11.
Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.
Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Pharm. 2015 Jan;21(1):37-44.
Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with Pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Pharm. 2014 Jun;20(6):603-10.
Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm. 2012 Jun 1;18(5):351-62.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009 Jul;68(7):1177-83. doi: 10.1136/ard.2008.094904
Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, Veale DJ. The development of the L-QoL: a quality of life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009 Feb;68(2):196-200. doi: 10.1136/ard.2007.086009
Herrinton LJ, Liu L, Shoor S, Mines D. Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis, 1996-2002. Ann Rheum Dis. 2008 Apr;67(4):574-5. doi: 10.1136/ard.2007.075986
Mines D, Gu Y, Liu Q, Horne LN, Harrison MJ. Risk of active tuberculosis (TB) among biologic-naïve RA patients: retrospective cohort study in a US claims database. Presented at the 2008 Annual European Congress of Rheumatology; June 2008. Paris, France. [abstract] Ann Rheum Dis. 2008; 67(Supplement II):91.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. Presented at the 2008 Annual European Congress of Rheumatology; June 2008. Paris, France. [abstract] Ann Rheum Dis. 2008; 67(Supplement II):51.
Bell C, Graham JB, Earnshaw S, Oleen-Burkey MK, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007 Apr 1;13(3):245-61.
Keenan A-M, McKenna SP, Doward LC, Conaghan PC, Emery P, Tennant A. OAQol: development and preliminary validation of a needs-based quality of life measure for osteoarthritis. Ann Rheum Dis. 2007;66:640.
Mines D. Attributing treatment as a cause in individuals and populations. Presented at the 2006 Annual European Congress of Rheumatology; June 22, 2006. Amsterdam, The Netherlands. [abstract] Ann Rheum Dis. 2006; 65(Suppl 2):15.
McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. The development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004 Feb 1;63(2):162-9.
Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003 May 1;9(3):223-31.
Doward LC, Spoorenberg A, Whalley D, Cook SA, Helliwell PS, Kay LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003 Jan 1;62(1):20-6.